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Abstract
Background: Community associated methicillin-resistant Staphylococcus aureus (CA-MRSA) is one of the most
common causes of skin and soft tissue infections in the United States, and a variety of genetic host factors are
suspected to be risk factors for recurrent infection. Based on the CDC definition, we have developed and validated an
electronic health record (EHR) based CA-MRSA phenotype algorithm utilizing both structured and unstructured data.
Methods: The algorithm was validated at three eMERGE consortium sites, and positive predictive value, negative
predictive value and sensitivity, were calculated. The algorithm was then run and data collected across seven total sites.
The resulting data was used in GWAS analysis.
Results: Across seven sites, the CA-MRSA phenotype algorithm identified a total of 349 cases and 7761 controls
among the genotyped European and African American biobank populations. PPV ranged from 68 to 100% for cases
and 96 to 100% for controls; sensitivity ranged from 94 to 100% for cases and 75 to 100% for controls. Frequency of
cases in the populations varied widely by site. There were no plausible GWAS-significant (p < 5 E −8) findings.
Conclusions: Differences in EHR data representation and screening patterns across sites may have affected
identification of cases and controls and accounted for varying frequencies across sites. Future work identifying these
patterns is necessary.
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Background
Methicillin-resistant Staphylococcus aureus is one of the
most common causes of skin and soft tissue infections
(SSTIs) in the United States [1]. Community-associated
methicillin-resistant Staphylococcus aureus (CA-MRSA)
has replaced traditional healthcare associated strains in
many communities where it previously did not exist [2, 3].
Recent reports indicate that CA-MRSA strains contain
more antibiotic resistance genes than previously
encountered, and pose an enormous concern for patients,
hospitals and public health entities [3]. Additionally, CA-
MRSA strains express increased virulence factors leading
to increased tissue destruction and more severe infections
[4, 5]. A variety of genetic factors are suspected as a risk
factor for recurrent CA-MRSA infection [4, 6, 7], with an
increased prevalence in younger, healthier populations
with no other identifiable risk factors [8].
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The Centers for Disease Control and Prevention (CDC)
definition of CA-MRSA distinctly differs from Healthcare-
Associated MRSA (HA-MRSA). A soft-tissue infection is
considered CA-MRSA if (1) a subsequently positive
wound culture was taken within 48 h of hospital admis-
sion [9, 10], and (2) the patient did not have surgery, live
in a long-term care facility, or undergo hemodialysis/peri-
toneal dialysis during the past year, and (3) the patient did
not undergo catheterization or insertion of indwelling per-
cutaneous devices during present hospital admission [3].
This definition was intended to clearly delineate commu-
nity and hospital acquired (HA) infections, with the pur-
pose of adequately differentiating the two phenotypes and
potentially guiding empiric therapy [11]. However, it is not
clear whether the criteria for CA-MRSA can readily trans-
late into a computable phenotype using electronic health
record (EHR) data (an increasingly common source for
clinical data) which can then be used for genetic analysis.
Identifying disease phenotypes using EHR data has
been a growing area of interest with the rapid increase
in EHR adoption nationally [12, 13]. The Electronic
Medical Records and Genomics (eMERGE) Network is a
national consortium consisting of 9 funded sites (in
phase II) formed to investigate the use of EHR systems
for genetic research, in which phenotype identification
algorithms can be proposed, disseminated and validated
[14, 15]. The eMERGE Network has developed numer-
ous phenotype algorithms using (EHR) data for use in
genetic analyses [15–19]. In this paper, we describe the
development and validation of a CA-MRSA case and
control phenotype algorithm, implementation results
and subsequent GWAS findings.
Methods
Algorithm development
The CA-MRSA phenotype algorithm was based on the
CDC definition and prior work in this space [3] and
developed at Northwestern University (NU). Figures 1
and 2 show the case and control phenotype definitions,
respectively. Case inclusion criteria included having a
bacterial culture drawn from a skin and soft tissue
(SSTI) infection site, in the outpatient or emergency de-
partment setting or within 72 h of admission to an in-
patient setting, which confirmed a MRSA infection. It
should be noted that the CDC definition considers
MRSA to be HA if the infection occurs >48 h after
admission, whereas we use ≥72 h in our definition to
minimize the possibility of incorrectly categorizing CA
as HA. Potential cases were excluded if the patient had a
hospitalization in the prior year before the MRSA infec-
tion, a prior stay in a long term care facility or nursing
home in the prior year, or had undergone catheterization
Fig. 1 Algorithm for the identification of patients with CA-MRSA
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or insertion of indwelling percutaneous devices during
the admission in which MRSA was detected.
Given a recent clinical trend to empirically treat pre-
sumed SSTIs as CA-MRSA without drawing cultures
[20], we also included “silver standard” criteria which re-
moved the requirement for microbiology confirmed
MRSA, and instead relied on clinical documentation of
International Classification of Diseases, Ninth Revision
(ICD-9) codes related to CA-MRSA infections, as well
as the presence of a SSTI within a week of initial diagno-
sis, to determine case status (Fig. 1). All ICD-9 codes
were based on the CDC definition for SSTIs associated
with MRSA [21] (Additional file 1: Table S1).
Due to the complexity of the phenotype, multiple data
inputs from clinical notes, records of past hospitaliza-
tions and laboratory culture results were needed to ac-
curately define the phenotype. We leveraged prior work
tracking MRSA within a health information exchange to
create a list of the most common terms used in EHRs
associated with SSTIs [22]. ICD-9 codes used to identify
SSTIs were based on the CDC definition for SSTIs asso-
ciated with MRSA [21].
Patients who had visited a primary care provider at
least two times within a continuous 3-year period (i.e.,
received “routine primary care”) and had never had a
positive MRSA screen, no prior history of an SSTI or
any MRSA infection were considered controls (Fig. 2).
Algorithm validation
The CA-MRSA phenotype algorithm performance was
validated via manual chart review for a set number of
randomly selected cases and controls, comparing the
outcome of the phenotyping algorithm to the “gold
standard” of individually abstracted information in the
patient charts to verify the correctness of case or control
status [18]. The algorithm was initially run, tested and
validated on patients’ biobank data at NU. The final al-
gorithm was then distributed to two other validating
sites (Geisinger Health System and Marshfield Clinic)
for implementation and validation. Implementation and
selection of cases and controls for validation of the
algorithm were completed using all patients’ data in each
site’s biobank. Charts for 50 cases and 50 controls were
reviewed at NU; 25 cases and 25 controls were reviewed
at Geisinger; 25 cases and 25 controls were reviewed at
Marshfield. Positive predictive value (PPV), negative
predictive value (NPV) and sensitivity were calculated at
each site individually. Additionally, at NU, all cases included
via the silver standard criteria alone were validated through
chart review. All statistical analyses were performed using
SAS 9.4 (SAS Institute Inc., Cary, NC, USA).
Phenotypic data
After outside site validation at Geisinger and Marshfield,
the algorithm was distributed to the other eMERGE sites.
In total, seven eMERGE institutions participated in this
study (Northwestern University, Geisinger Health System,
Marshfield Clinic, Children’s Hospital of Philadelphia
(CHOP), Group Health Cooperative, Mayo Clinic and
Vanderbilt University). Each site has robust genomic
biobank projects linked with EHR data, stored in their
site-specific data warehouses, for use in determining
genotype-phenotype associations. For purposes of this
study, patients with relevant EHR records were included
only if all genetic data necessary for GWAS was also
available. In addition to case and control status, age (at
time of infection for cases and at time of last visit for
controls), gender and race/ethnicity were also collected
from the EHR.
Genetic data
Details of the assembly of an imputed GWAS dataset for
the eMERGE II Network have been published previously
[23, 24]. In brief, SNPs were genotyped on a number of
different platforms at different sites. Data were quality
controlled at each site [25], then common SNPs were
merged. SNPs were imputed to the 1000 Genomes
Project phase 3 reference panel using IMPUTE [26].
Principal components fit to the pre-imputed SNP dataset
were computed using EIGENSTRAT [27].
Genetic analysis
GWAS analysis was run in SNPTest (version 2.4.1) [28] and
included only those patients with phenotypes, eigenvectors
and genetic information available. Models were stratified by
race (African American (AA) and European American (EA)
only, due to small sample sizes in all other groups)
determined from principal components analyses. After com-
pleting analysis, we filtered on imputation information >0.8,
minor allele frequency (MAF) ≥0.05, and Hardy-Weinberg
Equilibrium (HWE) >0.000001 to remove spurious
associations.
Fig. 2 Algorithm for the identification of CA-MRSA controls
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Results
When implemented on the entire biobank population at
each site, the CA-MRSA algorithm returned 124 cases
and 1649 controls at NU, 76 cases and 2310 controls at
Geisinger, and 61 cases and 7781 controls at Marshfield,
without inclusion of the silver standard criteria. Table 1
summarizes the validation results from all three sites.
PPV ranged from 68 to 100% for cases and 96 to 100%
for controls; NPV ranged from 90 to 100% for cases and
80 to 100% for controls; sensitivity ranged from 94 to
100% for cases and 75 to 100% for controls. Application
of the silver standard criteria did not yield significantly
more patients at any of the validation sites. Only four
additional cases at NU and four at Geisinger were identi-
fied after applying the silver standard criteria; no new
patients were identified at Marshfield. Chart review of
the “silver” cases at NU showed all four to be valid cases
of CA-MRSA.
Across all seven sites, the CA-MRSA phenotype algo-
rithm (including the silver standard criteria) identified a
total of 349 genotyped cases and 7761 genotyped con-
trols among the biobank populations. Table 2 shows the
breakdown of cases and controls by site. Addition of
silver standard criteria yielded a small number of add-
itional cases at some sites. Four sites (CHOP, Marshfield,
Mayo Clinic and NU) added no “silver” genotyped cases
(although, as described previously, some additional cases
were discovered in the entire biobank population). The
frequency of cases in the genotyped biobank sample also
varied widely by site, ranging from 0.1% (CHOP) to
13.1% (Geisinger). Table 3 shows patient demographic
characteristics, both overall and by case/control status
for all adult eMERGE sites. The demographic breakdown
of cases and controls by site and race can be found in
Additional file 2: Table S2. The CHOP site contributed
only 2 cases, and the demographics of cases and controls
were very different from all other eMERGE sites; as
such, GWAS analysis excluded data from this site.
Among the resulting sites, 5111 patients (269 cases;
4842 controls) were European American and 770 (71
cases; 699 controls) were African American. Only 0.9%
of cases and 0.8% of controls were identified as Hispanic
or Latino in the EHR. The majority of cases and controls
were female (52.4 and 61.9%) respectively. The average
age for cases was 42 (SD = 22); the average age for con-
trols was 67 (SD = 14).
There were no plausible GWAS-significant (p < 5E-8)
hits among the 269 cases and 4842 controls in European
Americans or the 71 cases and 699 controls in African
Americans (Additional file 3: Figure S1A and B). One
apparent signal in African Americans on chromosome 6
included only very low frequency SNPs in a gene desert,
suggesting that this result was a false positive. Examin-
ation of QQ plots and genomic inflation factors did not
suggest any systematic inflation from the null distribution.
Discussion
Development of an algorithm to capture a complex
phenotype like CA-MRSA poses several challenges. First
of all, the epidemiological definition of CA-MRSA by
the CDC is complex and has several requirements that
typically are not captured in structured data and instead
must be extracted from clinical and laboratory notes.
Therefore, our algorithm relied on each site’s ability to
combine data from multiple EHR sources, including
ICD-9 diagnosis codes, clinical notes, records of past
hospitalizations and laboratory culture results in order
to accurately extract phenotype cases and controls. The
extraction of information from non-structured fields re-
mains a significant obstacle to accurate phenotyping,
suggesting the need for text-based strategies, such as na-
tional language processing, for phenotyping.
Second, differentiation between hospital and community-
associated MRSA can be difficult. The issue is further com-
plicated because of increasing presence of CA-MRSA strains
in hospital settings and subcategories of HA-MRSA such as
healthcare associated community onset (HACO) [29] and
healthcare associated hospital onset (HAHO) [30] MRSAs.
Our phenotype definition expands on previous epidemio-
logic studies by Casey et al. [31, 32], in which HA-MRSA is
differentiated from CA-MRSA primarily by having an in-
patient visit at the time of positive MRSA culture/diagnosis,
an indwelling catheter or subcutaneous device at the time of
positive MRSA culture/diagnosis, or a hospitalization,
dialysis, surgery or residence in a nursing home within the
year prior to a positive MRSA culture/diagnosis at a single
Table 1 Summary of chart review validation
Cases Controls
Northwestern Geisinger Marshfield Northwestern Geisinger Marshfield
Total Na 124 76 61 1649 2310 7781
Total Reviewed 50 25 25 50 25 25
Sensitivity 0.94 1 1 0.75 0.96 1
PPV 0.68 0.96 1 0.96 1 1
NPV 0.90 1 1 0.80 0.96 1
aSample includes all patients in site’s biobank
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healthcare system. Our study took place at seven institu-
tions, spanning various EHR systems, each with unique
complications to obtaining note-based requirements. There-
fore, to increase the likelihood that the MRSA infection was
community associated, we included a requirement that the
site of infection must be an SSTI, in case of sparse clinical
notes. Similarly, we required that any diagnosis of CA-
MRSA be combined with an SSTI diagnosis within the week
before or after the MRSA diagnosis. These differences may
account for significant variation in performance of CA-
MRSA case definitions, and as such, may also help explain
the differences in frequency of cases across sites.
While our final cohort of patients included cases and
controls from multiple institutions spanning urban, sub-
urban and rural geographies across the country, each in-
dividual site’s cohort only included information from
one institution. Prior work has demonstrated significant
fragmentation of key data on MRSA across institutions
[22, 33]. Indeed, during the validation process, chart re-
viewers noted that many patients not excluded from the
case definition in the algorithm were found to have been
hospitalized and/or underwent surgery at sites other
than the institution where the CA-MRSA culture was
drawn and, therefore, were incorrectly included as cases
by the algorithm. Again, this supports the need for text-
driven strategies in defining phenotypes, as well as
effective health information exchange in regions in
which overlap of patient populations across multiple in-
stitutions is significant.
The frequency of cases among the biobank popula-
tions varied widely between each site. This algorithm
was run at a total of seven sites which collectively repre-
sent a diverse population of patients, clinicians, EHRs
and conventions of documentation. While this variety
enhances diversity of the population for analyses, it also
provides a challenge to EHR extraction. Additionally,
our study included only patients who also had genetic
information captured as part of each institution’s bio-
bank. This may account for some of the cross-site differ-
ence in case numbers used for analysis, particularly if
biobanking efforts focused on specific populations. Our
sites represent a sample of larger healthcare delivery in-
stitutions and are located in areas with differing rates of
CA-MRSA [34]. Institutional differences in screening
practices (e.g., mandated active surveillance of specific
populations) for MRSA may have also accounted for
cross site differences in the frequency of cases among
the genotyped populations from the biobank [35, 36].
Selection of a set number of cases and controls for val-
idation purposes (rather than selecting numbers propor-
tional to the prevalence of each group in the study
population) may have led to inflation of sensitivity esti-
mates due to validation bias. Given the low frequency of
MRSA in this population, we felt enrichment of cases
for validation was necessary. As all sites validated the
same ratio of cases and controls, we anticipate this infla-
tion to be similar across all three validation sites.
Small sample size was a limitation of our study. Original
application of the algorithm at the three validation sites
(NU, Geisinger and Marshfield) returned only 112 valid
cases to be used in the final GWAS. The ICD-9 based “sil-
ver” criteria were added in order to obtain additional cases
to increase GWAS power. However, despite anecdotal
evidence that front-line clinicians empirically treat all sus-
pected CA-MRSA patients and do not routinely draw
wound cultures, we identified very few new cases of CA-
MRSA using ICD-9 codes alone that were not otherwise
Table 2 Summary of genotyped case and control subject countsa by institution
Overall CHOPb Geisinger GHC Marshfield Mayo NU VU
Total Cases 349 2 34 39 15 1 62 196
Silver Only 40 0 1 1 0 0 0 38
Total Controls 7761 1869 233 1131 1871 306 783 1568
Prevalence 4.3% 0.1% 12.7% 3.3% 0.8% 0.3% 7.3% 11.1%
aSample includes only GWAS genotyped patients from the site’s biobank
bCHOP data was not included in GWAS analysis
Table 3 Demographics of cases and controls in GWAS
Overall Cases Controls
N (%) N (%) N (%)
Total 6239 347 (5.6) 5892 (94.4)
Sex
Male 2407 (38.6) 165 (47.6) 2242 (38.1)
Female 3832 (61.4) 182 (52.4) 3650 (61.9)
Ancestry
European American 5111 (81.9) 269 (77.5) 4842 (82.2)
African American 771 (12.4) 72 (20.8) 699 (11.9)
Hispanic 14 (0.2) 0 (0) 14 (0.2)
Other 343 (5.5) 6 (1.7) 337 (5.7)
Ethnicity
Hispanic or Latino 49 (0.8) 3 (0.9) 46 (0.8)
Not Hispanic or Latino 6076 (97.4) 340 (98.0) 5736 (97.4)
Unknown 114 (1.8) 4 (1.2) 110 (1.9)
Age (years) (mean(SD)) 66 (16) 42 (22) 67 (14)
Jackson et al. BMC Infectious Diseases  (2016) 16:684 Page 5 of 7
picked up by the original definition (n = 8 in the entire bio-
banked sample). Due to the small counts and 100% accuracy
of patients obtained at NU, we did not require that other
sites validate the “silver” algorithm. This criteria required an
ICD-9 code for CA-MRSA, which clinicians may not often
use to characterize SSTIs without the availability of con-
firmatory cultures (i.e., preference for the use of ICD-9
codes for “Abscess” or “Cellulitis” when culture has not been
performed), and is largely physician dependent. The lack of
frequent clinician documentation using these ICD-9 codes
may be responsible for low patient numbers falling into this
category and currently limits the utility of this approach.
Further research into the EHR-based documentation pat-
terns of clinicians for SSTIs that represent suspected CA-
MRSA cases will help address these concerns.
The lack of GWAS-significant findings in either European
or African Americans is disappointing, but not surprising
given the limited sample size and anticipated modest effect
size of any common genetic variants pre-disposing to CA-
MRSA infection [6, 7, 37]. With CA-MRSA cases not de-
fined in a uniform manner (as detailed above) and not
screened for in a uniform manner (also detailed above),
measurement error in the identification of cases would be
expected to bias any association estimates between SNPs
and CA-MRSA to the null. Despite these reports, differences
in rates of host susceptibility to Staphylococcus aureus
colonization and infection and differences in susceptibility
to severity of related diseases point to a role for host genetic
factors in susceptibility to CA-MRSA infections [6].
Conclusion
The algorithmic extraction of CA-MRSA cases and controls
from EHRs presents challenges and new possibilities for
phenotypic-genotypic association studies. Our algorithm
represents, to our knowledge, a first attempt at validating an
otherwise complicated phenotype across multiple care sites.
Variation in patient populations, screening practices, con-
ventions of documentation and EHR data capture make
standardization of an algorithm challenging and may ac-
count for variation in algorithm performance. Future work
should focus on identifying these specific differences, as ac-
counting for institutional variations when defining the algo-
rithm may assist in identifying additional valid cases and
controls to provide additional power to detect genetic risk
factors predisposing carriers to CA-MRSA.
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